Annals of Oncology

Article	Citations
342eP Multiomic characterization of early and metastatic biliary tract cancer (BTC)	1451
505eP Real-world efficacy of anlotinib in bevacizumab-treated gastrointestinal cancers	1198
501P Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal (GI) adenocarcinoma undergoing syste	1009
307P AI-driven patient screening for clinical trials in pancreatic cancer: Integrating LLMs with tumor board meetings	769
300P Clinical, pathological, and genomic biomarkers associated with early recurrence in resected localized pancreatic ductal adenocarcinoma (L-PDAC)	695
327P Real world evidence of outcomes and treatment patterns for advanced biliary tract cancer in Saudi Arabia	603
16P Early ctDNA decrease predicts survival in MSI metastatic colorectal cancer treated with immunotherapy	581
139eP Real-world practice of MSI/MMR testing and treatment patterns in colorectal cancer: A nationwide survey in China (SUMMER study)	560
251P Clinical outcomes of rectal squamous cell carcinoma in British Columbia, Canada	546
92P Real-world evidence of a tissue-free ctDNA-based minimal residual disease (MRD) testing in colorectal cancer (CRC): Insights from an Indian cohort	505
195P Risk factors in patients with hepatocellular carcinoma: A German claims data analysis	462
285P Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial	413
77P Chronologic improvement in survival of first-line oxaliplatin based chemotherapy + targeted therapy for metastatic colorectal cancer (mCRC): Analysis of the ARCAD database	394
178P Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: An updated meta-analysis and meta-regression of obser	390
476P How to predict microsatellite instability (MSI) status in locally advanced gastric cancer? A preoperative CT-based proposal	355
19P Adjuvant chemotherapy in colon cancer: 6 months better than 3?	354
215P Peptide receptor radionuclide therapy versus capecitabine/temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors	347
225P Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors	313
468P Association of prior and concurrent malignancies with overall survival in a large European single-center gastroesophageal cancer cohort	296
459P Layer analysis based on RNA-seq data of TCGA reveals gastric cancer's molecular complexity	283
133P The role of determining the diagnostic value of circulating tumor DNA (ctDNA) and natural blood killers (NK) in the diagnosis of precancerous diseases of the colon and colorectal cancer (CRC)	275
Identifying genetic loci associated with an increased risk for early-onset colorectal cancer	275
45P Neoadjuvant immunotherapy with prolgolimab in locally advanced MSI/dMMR colorectal cancer: Safety and efficacy analysis	275
13P Genomic signatures of recurrence after resection of node-negative colorectal cancer	270
Table of Contents	265

386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)	258
546P An artificial intelligence system integrating deep learning-proteomics, pathomics and clinicopathological features to determine risk of T1 colorectal cancer metastasis to lymph node	242
CN100 Scalp cooling in breast cancer: What are women's experiences? A description and qualitative study	232
28P Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy	229
1906P ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy	223
897P Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma	220
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part	196
1069TiP A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies	190
1768P Desmoid tumors: Experience of a Spanish reference center	186
1270P Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial	177
1339P Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC	177
420P An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples	177
2007P Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials	177
87P Application of tissue and liquid-based next generation sequencing (NGS) for comprehensive genomic profiling: Evaluating the clinical value of ctDNA technology in treatment decision making	174
199P Association of homologous recombination deficiency status with outcomes for ovarian cancer patients treated with olaparib, and exploration of other biomarkers of relapse and survival	174
913P Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer	171
CN107 The effect of Orem-based oral self-care protocol on high-dose chemotherapy-related oral mucositis and self-care agency in patients for hematologic malignancies: A randomized controlled study	169
1915P Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma	166
568P Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort	164
653P A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors	164
1990P MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study	159
1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)	158
383P Clinical experience with TTX-MC138: A first-in-class therapy against metastatic cancer	156
473P A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)	149
1203P Analytical evaluation of whole genome sequencing for acute myeloid leukemia	149
1493P The Italian version of the FAMCARE-P13 questionnaire: A validation study	148
1992P Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (N	141
2009P PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (c	138
CN11 The challenges of the multidisciplinary work of nurses in the international department at Gustave Roussy Cancer Campus	134
1385P Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma	134
Imatinib’s last lessons? A roadmap to cure	133
495TiP CLARITY-Gastric 01: A randomised phase III study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junct	131
344P Treatment intensification patterns in Asian patients with metastatic hormone sensitive prostate cancer (mHSPC)	127
415P Preliminary safety and efficacy results from phase II study pulsed radiotherapy with tislelizumab in patients with recurrent head & neck cancer	124
193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma	124
503P Retrospective evaluation of real-world experience and usefulness of implementing next-generation sequencing in clinical oncology: Insights from a developing Asian country	122
643P Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE	121
387P COL4A6 promotes tumor progression and chemoresistance in ovarian cancer by activation DDR1 pathway	119
565P Prevalence of multi-drug resistant bacteria among neutropenic cancer patients and its association with 30-day mortality: A single centre study from a regional cancer centre	117
501P Comparison between tissue and ctDNA for detecting tumor mutation burden (TMB) across solid tumors: A single centre study from India	115
1829P Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial	114
259P Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: A prospective, multi-center, observational real-world study	109
349P Predictive gene signature in primary prostate cancer associated with regional lymph-node metastasis using both mRNA and miRNA profiling	108
475P Impact of palliative care on the quality of life in advanced non-small cell lung cancer patients: A longitudinal study	108
217P The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction	108
339P Comparison of stereotactic body radiation therapy(SBRT) and radical prostatectomy (RP) in high-risk/very high-risk prostate cancer: A large multi-center comparative analysis using propensity scor	107
546P Multifaceted challenges in patient-centered oral cavity cancer care: An Asia-Pacific cross-sectional study with patients, caregivers, and healthcare professionals	106
596P Innovative multimodal deep-learning model for real-time prediction of recurrence in early-stage NSCLC	106
699P Osimertinib combined with chemotherapy as first-line treatment in EGFR-mutant advanced NSCLC patients: The first real-world analysis in China	105
581P Informal caregiver mental health and time cost for stomach and pancreatic cancer care	104

231P CT image-based artificial intelligence quantification of intratumoral heterogeneity for predicting treatment response to immunotherapy combined with anti-angiogenic drugs in hepatocellular carcin	101
709P The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%	100
589P Patient centricity in cancer: Overview past and current applications of patient reported outcomes	99
237P Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in hepatocellular carcinoma with severe macrovascular invasion: A retrospective cohort study	99
131MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported	98
483MO RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma	96
178P KEYNOTE-859 update: Pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer	94
482MO Clinical usefulness of next-generation sequencing for metastatic or unresectable gastric cancer in molecular profiling-guided therapy era	91
517P Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer: An interim report	91
781P Prognostic role of targeted amino acids as oncometabolites in acute lymphoblastic leukemia	90
821P Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma	88
554P Clinical outcomes of treating patients in prone compared to supine position for breast radiotherapy: A systematic review and meta-analysis	88
162P Efficacy of perioperative FLOT in gastric carcinoma and gastroesophageal junction carcinoma in achieving PCR: Retrospective analysis in a single institution experience	88
285O Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study	87
1242MO The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer: A randomized controlled, open-label phase II study	87
666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients	87
1936P Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling	86
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment	86
244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)	85
11P Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer	84
Title Page	84
CN14 Cancer prevention awareness among Croatian AYA population	83
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches	82
51P Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity	82
82P Obtaining microvesicles from T-lymphocytes using various methods of induction	81
1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell	79
332P Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study	79
166P Metabolomic prediction of breast cancer treatment toxicities	79
1310P Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes	78
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhi	78
2335P Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma	78
1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)	77
179P Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study	77
1O CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites	76
1905P Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma	75
2092P Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors	74
14P Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy	74
1590P Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)	74
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study	73
878P INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype	72
1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma	71
1601P Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy	71
809P Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship	71
CN69 Experiences of patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A qualitative study	71
2067P Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data	71
1296P Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial	70
1589P Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin	70
1608P Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy	70
CN55 The impact of psychosocial support on the overall health of cancer patients in the COVID-19 era	70
1232P Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification	69
2173P Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital	69
515P A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients	69
577P Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer	68
578P Tissue-resident microbiota characterization in colorectal cancer metastases	68
1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)	67
1921MO Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies two prognostic profiles: A cohort study from the French Sarcoma Group (FSG)	66
2132P Unmet needs, quality of life, and financial toxicity in survivors of lung cancer	65
1939P phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients	65
MO60-4 Tryptophan is the prognostic factor in patients with unresectable pancreatic cancer	65
1997P A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer	65
365P Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis	64
56P SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume	64
1677P Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma	64
402O A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary	64
1651P Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy	64
457P Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting	64
2272P Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)	63
1723P Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands	63
1122P Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?	63
22P Clinical significance of DNA damage response mutations in early stage NSCLC	62
1593MO Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China	62
121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium	61
49P Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer	61
MO48-4 Efficacy and quality of life in blinatumomab treatment in patients with acute lymphoblastic leukemia: Systematic review	61
1681P A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer	61
1702P Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022	59
2116P Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea	58
907P Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II	57
971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China	57
MO68-4 A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5	56

936P Triple oral metronomic chemotherapy (OMCT) versus physician choice chemotherapy after failure of platinum-based therapy in advanced head and neck squamous cell cancer (HNSCC): A phase III randomi	56
2276P Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer	55
505P Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial	54
1707P Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology	54
995P Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada	53
201P A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma	53
2293P Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers	53
329P Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy	53
1673P Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study	53
1274P Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer	52
195P Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis	52
622P A prognostic and immune infiltration analysis of CCL26 in pan-cancer	52
2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small ce	52
213P Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastati	51
430P Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries	51
243P Targeting autophagy in tumor-associated macrophages effects the phenotype and tumor progression in urothelial carcinoma of bladder	51
113P Molecular profiling of biliary tract cancers in patients of African and European ancestries	51
34P Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer	50
414P Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis	50
2285P Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls	49
268P Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study	49
375P Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital	49
331MO Comparing data distribution and prognosis of acute myeloid leukemia according to 5th WHO classification and international consensus	49
398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure	48
451P The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia	48
404P Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India	48
350P Primary prevention of chemotherapy-induced neutropenia in patients with advanced lung cancer in real-world research	47
336P Prognostic and predictive value of Immunoscore in stage III colorectal cancer in the combined SCOT and IDEA-HORG studies	47
P-85 Treatment propensity and the feasibility of cisplatin plus gemcitabine in elderly patients aged ≥ 75 years with biliary tract cancer	47
431P Alveolar soft part sarcomas: A tertiary care Indian centre experience	47
P-332 Characteristic and clinical outcome of localized gastric cancer; real-world data	47
JS01-3 Optimizing cancer genome medicine in clinical practice in Japan	46
MO36-5 Non-familial prospective risk factors in predicting cancer of unknown primary: A systematic review and meta-analysis	46
LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, op	46
P-202 Topical diclofenac in prevention of capecitabine-associated HFS in patients with GI cancers: An exploratory subgroup analysis of the D-ToRCH study	46
MO6-5 Tumor microenvironment and clinical efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma	46
1046P Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)	45
1704P Multimodal approach to discover novel targets for antibody-drug conjugates by analyzing distinct expression patterns of frequent copy number aberration	45
1485O Percutaneous uterine needle biopsy with microscopic and array-CGH analyses in patients with suspicious myometrial tumors on MRI: A prospective study	45
ME07 New treatment strategy for hepatobiliary cancer	45
1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)	44
CN28 Impact of serious illness care program to patients with hematopoietic stem cell transplantation on goals of care documentation and acute healthcare utilization	44
1076P Cancer cachexia associated with gut microbiota and clinical outcomes of patients with non-small cell lung cancer amenable to immunotherapy	44
1520P Preferences on treatment decision making in sarcoma patients. Prevalence and associated factors: Results from the PROSa study	44
52P HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1	44
LBA32 Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (phase II): Safe and effective in both PD-L1 positi	44
LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation	44
1295TiP Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy	44
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)	43
450O Initial monotherapy results of a phase I first-in-human study of ULK1/2 inhibitor DCC-3116 alone and in combination with MAPK pathway inhibition	43
1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study	43
140P Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience	42
1310MO Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study	42
1779TiP Phase II clinical study evaluating the efficacy and safety of disitamab vedotin in patients (pts) with HER2-expressing urothelial carcinoma (RC48G001)	42
342P A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients	42
373P Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2	41
461P Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India	41
720P Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence	41
85P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXI	41
37P Development of splice switching antisense oligonucleotides targeting midkine	40
121P Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data	40
1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial dis	40
70P Genetic alterations and immune cell infiltration with potential impact on PD-(L)1 targeted treatment in various cancer entities: Biobank research project of the INFINITY registry	39
P-225 Appraising the potential causal relationships between gut microbiota and colorectal cancer: A two-sample Mendelian randomization analysis	39
Notice and Disclaimer	39
P-111 Increased risk of pancreatic cancer among 141,387 diabetic patients treated with DPP-4 inhibitors analyzed with common data model	39
P-177 Sex differences in chemotherapy-induced toxicities in gastric cancer patients	39
201P Metastatic and survival characteristics of de novo versus relapsed breast cancer in females aged>35-years-old: A nationwide multicenter study based on hospital population	39
202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibito	39
P-160 Primary gastrointestinal lymphoma in Latin American patients. A 10-year follow-up	39
O7-4 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16	39
212P A cohort study on the immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with breast cancer: Does trastuzumab interfere with the outcome?	39
12P Any size of lymph node metastasis should be considered N1 in patients with cervical cancer	39
553P Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the	39
39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients	39
238P Budget impact analysis for the health care package by using MammaPrint in Belgium	39
MO45-3 The efficacy of osimertinib in patients with EGFR-positive non-small cell lung cancer with malignant pleural effusion	39
P-184 Prognostic value of mTOR expression and mismatch repair gene profile in advanced gastric and gastro-oesophageal cancer	39
MO38-2 Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumors	39
1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)	38
224P Adherence to adjuvant hormonal therapy in patients with localized breast cancer	38
SO-10 The prognostic role of microarchitecture in tumour-positive lymph nodes in oesophageal cancer patients: Results from the UK MRC OE02 trial	38
P-200 Mutational testing on liquid biopsies for treatment decisions in metastatic colorectal cancer – comparison of ddPCR and MassARRAY methods	38
P-285 Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study	37
44P Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas	37
P-173 Understanding the treatment algorithm of patients with advanced G2 gastroenteropancreatic neuroendocrine neoplasms: A single-institution retrospective analysis	37
1451MO In-situ immune markers predict nivolumab (N) +/-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized tria	37
P73-4 Experience with nivolumab in advanced metastatic gastric cancer	37
1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France	36
P-291 PIK3CA mutations in Tunisian patients with metastatic colorectal cancer: Patient stratification for targeted therapies	36
554P Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study	36
SY01-1 Novel therapies and Immunotherapy for small cell lung cancer: Finally, some progress	36
P-42 How to improve outcome in high-risk stage III colon cancer with dMMR gene	35
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data	35
SY12-3 Precision medicine for esophageal cancer	35